Trevi Therapeutics, Inc. (TRVI) Stock Overview
Explore Trevi Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Trevi Therapeutics, Inc. (TRVI)
Key Financials
Key Financials
Market Cap
2.1B
P/E Ratio
-43.49
EPS (TTM)
$-0.34
ROE
-0.24%
TRVI Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Trevi Therapeutics, Inc. (NASDAQ: TRVI) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Trevi Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TRVI on the NASDAQ shows an RSI of 27.28, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $19.98 for the NASDAQ listing.
Key metrics behind Trevi Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -43.49 and a market capitalization of 2.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TRVI on the NASDAQ.